Please see full prescribing and safety information, including boxed warning, for PACLITAXEL multi-dose vials.
Available in:
- 30 mg per 5 mL multi-dose vials
- 100 mg per 16.7 mL multi-dose vials
- 300 mg per 50 mL multi-dose vials
Benefits:
- AP Rated
- Preservative-free
- Not made with natural rubber latex
Downloads:
PACLITAXEL Injection, USP*
Brand Name Equivalent: TAXOL® (TAXOL is a registered trademark of Ingenus Pharmaceuticals LLC.)
Therapeutic Category: Antineoplastic Agent
PreventIV Measures® Features:
- Easy-to-read drug name and dosage strength to aid in identifying the right product
- Bar codes included on the vial and carton for ease of scanning
- Unique label design to help products stand out on the shelf
- Enhanced packaging and labeling designed to promote safety and help reduce the risk of medication errors
| NDC #25021 |
Description | Strength | Fill Volume |
Concentration | Container Size |
Closure | Unit of Sale |
| 255-05 | Glass Vial | 30 mg | 5 mL | 6 mg per mL | 5 mL | 13 mm | 1 |
| 255-17 | Glass Vial | 100 mg | 16.7 mL | 6 mg per mL | 20 mL | 20 mm | 1 |
| 255-50 | Glass Vial | 300 mg | 50 mL | 6 mg per mL | 50 mL | 20 mm | 1 |
WARNING
Paclitaxel Injection, USP should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available. Anaphylaxis and severe hypersensitivity reactions characterized by dyspnea and hypotension requiring treatment, angioedema, and generalized urticaria have occurred in 2% to 4% of patients receiving paclitaxel in clinical trials. Fatal reactions have occurred in patients despite premedication. All patients should be pretreated with corticosteroids, diphenhydramine, and H2 antagonists. (See DOSAGE AND ADMINISTRATION section.) Patients who experience severe hypersensitivity reactions to paclitaxel should not be rechallenged with the drug. Paclitaxel therapy should not be given to patients with solid tumors who have baseline neutrophil counts of less than 1,500 cells/mm3 and should not be given to patients with AIDS-related Kaposi’s sarcoma if the baseline neutrophil count is less than 1,000 cells/mm3. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving paclitaxel.